drugset / Trial / NCT07427394
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
A study to investigate camizestrant in combination with atirmociclib in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.
Timeline
- Start
- 2026-05-06
- Primary completion
- 2027-12-03
- Completion
- 2027-12-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atirmociclib | Small molecule | — | Oral |
| Subject | Camizestrant | Other / unclassified | — | Oral |